title: Immunohistochemical Profiling of Endometrial Serous Carcinoma.
abstract: Endometrial serous carcinoma (ESC) is an aggressive neoplasm mainly seen in older women. The objective of this study was to refine immunohistochemical (IHC) panels for the differential diagnoses against endometrial endometrioid grade 3 (EC3), endometrial clear cell, and ovarian high-grade serous carcinoma as well as exploring the prognostic role of selected IHC markers. Fifty-two ESC from a single institution were assessed for 20 IHC markers, including ARID1A, CCNE1, CDKN2A, ERBB2, ESR1, HNF1B, FBXW7, IGF2BP3, MLH1, MSH2, MSH6, NAPSA, PAX8, PGR, PMS2, PTEN, TFF3, TP53, VIM, and WT1. ERBB2 chromogenic in situ hybridization was evaluated on tissue microarrays. Statistical analysis was performed. All ESC showed aberrant TP53, normal mismatch repair protein, and retained ARID1A and PTEN expression. ESR1 expression was present in 80% of ESC. A combination of TP53, PTEN, and CDKN2A had a sensitivity of 93.6% [95% confidence interval (CI), 84%-98%] and specificity of 87.8% (95% CI, 75%-95%) for ESC versus EC3. A combination of NAPSA and ESR1 had a sensitivity of 97.9% (95% CI, 89%-99%) and specificity of 72.2% (95% CI, 46%-90%) for ESC versus clear cell carcinoma. Absence of WT1 alone had a sensitivity of 66.0% (95% CI, 51%-79%) and specificity of 98.0% (95% CI, 94%-99%) for ESC versus ovarian high-grade serous carcinoma. Among all 52 ESCs, ERBB2 amplification was present in 23%, FBXW7 expression was absent in 10%, and CCNE1 was overexpressed in 59%, however, none were associated with prognosis. Our data support the value of IHC marker panels for histotyping of high-grade endometrial carcinomas.
authors.affiliation: Department of Pathology and Laboratory Medicine (W.C., P.F.R., S.Liu., S.Lee., M.A.D., M.K.), University of Calgary Division of Gynecologic Oncology (G.S.N.), Tom Baker Cancer Centre, Calgary Department of Pathology and Laboratory Medicine (C.H.L.), University of Alberta Division of Pathology and Laboratory Medicine (A.H.), Chinook Regional Hospital, Lethbridge, AB, Canada.
authors.forename: Wenqian
authors.initials: W
authors.lastname: Chen
authors.forename: Arjumand
authors.initials: A
authors.lastname: Husain
authors.forename: Gregg S
authors.initials: GS
authors.lastname: Nelson
authors.forename: Peter F
authors.initials: PF
authors.lastname: Rambau
authors.forename: Shuhong
authors.initials: S
authors.lastname: Liu
authors.forename: Cheng-Han
authors.initials: CH
authors.lastname: Lee
authors.forename: Sandra
authors.initials: S
authors.lastname: Lee
authors.forename: Máire A
authors.initials: MA
authors.lastname: Duggan
authors.forename: Martin
authors.initials: M
authors.lastname: Köbel
mesh_terms: D018262:Adenocarcinoma, Clear Cell / Q000175:diagnosis; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000032:analysis*; D018269:Carcinoma, Endometrioid / Q000175:diagnosis; D018284:Cystadenocarcinoma, Serous / Q000175:diagnosis*; D003937:Diagnosis, Differential; D016889:Endometrial Neoplasms / Q000175:diagnosis*; D005260:Female; D020869:Gene Expression Profiling / Q000379:methods*; D006801:Humans; D007150:Immunohistochemistry; D017403:In Situ Hybridization; D008875:Middle Aged; D012189:Retrospective Studies; D012680:Sensitivity and Specificity; D046888:Tissue Array Analysis
chemical_list: D014408:Biomarkers, Tumor